Zoledronate ( DrugBank: Zoledronate )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 1 |
| 65 | 原発性免疫不全症候群 | 1 |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800019277 | 2018-11-01 | 2018-11-02 | The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients | The Zoledronic Acidameliorate theSecondary Osteoporosis in Rheumatoid Arthritis patients | Rheumatoid Arthritis | Control group:MTX;Treatment group 1:Zoledronate Acid(ZA);Treatment group 2:MTX+Zoledronate Acid; | Shanghai Traditional Medicine University Affiliated Guanghua Hospital | NULL | Recruiting | 18 | 65 | Both | Control group:22;Treatment group 1:22;Treatment group 2:22; | China |
65. 原発性免疫不全症候群
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000013102 | 2014/03/10 | 01/03/2014 | Efficacy of Zoledronate for RAS associated ALPS like disease (RALD) | RAS associated ALPS like disease (RALD) | intravenous drip infusion of Zoledronate | Department of Pediatrics, Tokyo Medical and Dental University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 5 | Not selected | Japan |